🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

PEACE 3 by silke gillessen at #ESMO2024 Radium-223 added to enza vs enza alone in mCRPC (mostly mot previously exposed to ARPI): Improved ✅PFS ✅OS ✅time to next treatment No major safety signal if bone protecting agents used. What impact given ARPI use at mHSPC?

Excellent discussion of pitfalls and practical implications of the PEACE 3 data by Prof Karim Fizazi. 1. Clinical benefit clear PFS/OS 2. Fracture prevention 3. BP monitoring 4. Only for ARPI naive pts 5. More data to come! #ESMO2024

Dr Grist AttardLab at #ESMO2024 Decipher by Veracyte DECIPHER prognostic for OS in mHSPC but most importantly predictive for efficacy of docetaxel. Not predictive for Abi effect.

Dr Pobel at #ESMO2024 presenting the molecular analysis of the PEACE 1 trial. Identifies molecular phenotypes and prognostic markers but no interaction with abiraterone efficacy Major undertaking by GETUG Gustave Roussy Yohann Loriot.

Another ARPI in 1st line therapy for mHSPC: ARANOTE trial presented at #ESMO2024 & published simultaneously at Journal of Clinical Oncology Darolutamide improves all endpoints (rPFS, time to CRPC, time to pain, deep PSA response...), OS immature No safety concern (less fatigue with daro vs PBO!)

Transdermal estradiol as a new option for testosterone lowering vs LHRHa : similar MFS & OS but different toxicity than LHRHa (less hot flashes, higher bone mineral density...) Open Qs: 1. efficacy vs antagonists 2. combination with other drugs (ARPI, PARPi) or RT #ESMO2024

To be presented during ASTRO 2025 🇺🇸 Nicolas Demogeot Supiot Stéphane Jonathan Khalifa 🎗️ Hennequin Christophe Azria David GETUG sciencedirect.com/science/articl…

⚡Before PEACE 1 to be published soon, read our short update on local and metastases directed treatments for MHSPC #ProstateCancer ✨✨ Nicolas Benziane-Ouaritini And Alberto Bossi ⚡Just out In Eur Urol Focus sciencedirect.com/science/articl…

PEACE-1 RT is now published online at The Lancet Some differences with STAMPEDE Key messages: RT to prostate in M1 #prostatecancer 1. improves rPFS but not OS in low volume 2. improves CRPC-FS & reduces serious GU SAE irrespective of volume Full text: thelancet.com/journals/lance…

Big news👋. A positive R3 trial for PD-1 in NMIBC! The CREST trial evaluated sasanlimab (PD-1i)+BCG vs Standard BCG (induction and maintenance) in BCG-naïve, high-risk NMIBC.The study met its primary endpoint of EFS with ‘clinically meaningful’ results. pfizer.com/news/press-rel…

Combined approaches result in 9-year prostate cancer specific survival ranging between 96.1% and 100% ✴️PEACE 7 TRIAL to be started soon: SOC +/- Darolutamide +/- SBRT boost ... GETUG Association Française d'Urologie - AFU @sfro_fr karim fizazi EORTC ANAMACaP Advanced Prostate Cancer Consensus Conference Prostate Cancer Foundation

2years of ADT after radical prostatectomy for high Risk #prostate #cancer patients did not improve MFS in phase III RCT AFU-GETUG 20 trial. #GU25 Need to identify better biomarkers of relapse Association Française d'Urologie - AFU GETUG Pr. Alexandre de La Taille Morgan Roupret Ploussard Guillaume

⁦GETUG⁩ V04 randomized study on Gem/Cis chemoradiation for #bladdercancer presented by ⁦Morgan Michalet⁩. Surprising lower survival (NS but small cohort) that may be a cause of concern. Related to higher metastases in Gem/Cis group. #ESTRO25

Paul Sargos presenting very reassuring early toxicity results from GETUG adjuvant radiotherapy trial after cystectomy for #bladdercancer #ESTRO25

10y results of FAST FORWARD (adjuvant #breastcancer RT) trial presented at #ESTRO25 by AM Brunt. Compared to 40Gy/15, 26Gy/5: 1. Non inf for IBR (even superior?) 2. Similar recurrence free interval, breast cancer interval, OS 3. No diff in PRO or toxicity Clearly 26/5 SOC for

🚨Birgitte Offersen reports on SKAGEN-1 trial of hypofractionation (40/15 vs 50/25) #ESTRO25 1. Safe: similar lymphedema 2. Effective: similar locoregional and distance recurrence, OS BUT increased #breastcancer mortality, across subgroups & w/o explanation. Discussions to follow…

Words of wisdom from Michael Baumann, MD on the future of radiation oncology, recipient of the 2025 Jens Overgaard award. Well deserved! #ESTRO25

Pierre Blanchard, MD GETUG Impressive curves despite the phase 2 design 👌

STORM-PEACE V trial reported by Thomas Zilli #ESTRO25 Pelvic ENI superior to MDT for pelvic relapses after local Tx for #prostate cancer (6mo ADT each) Improves Biochemical PFS Locoregional PFS MFS ADT free survival Tox NS ENI clear SOC Online The Lancet Oncology Cc Piet Ost

📢Delighted to share a new publication in Annals of Oncology. PEACE III is the first major Phase III trial to combine an ARPI with radiopharmaceutical that showed statistical significance in meeting the primary endpoint bit.ly/PeaceIII